We know there are critics of these decisions, both in the U.S. and in Canada. As we said, there are risks with every product, and those do occur. So we are mindful and very obligated to continue to monitor those very carefully, and should a change be required in the kinds of approval conditions we've given, then we will certainly act.
So we review this continuously. There are always different points of view on many of these kinds of issues, and given this one, I think that's to be expected. We will continue to track it very carefully, as we know the FDA is as well. We're certainly in contact with them and with other regulators around the world. So we feel that internationally there's a lot of attention on these products, and we will have access to information from around the world as it becomes available.